We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 77.51%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARCT icon
51
Arcturus Therapeutics
ARCT
$382M
$11.7M 0.1%
255,696
– –
MGNX icon
52
MacroGenics
MGNX
$261M
$11.6M 0.1%
305,043
– –
AGIO icon
53
Agios Pharmaceuticals
AGIO
$1.98B
$11.1M 0.1%
100,000
-49,954
-33% -$5.38M
LJPC
54
DELISTED
La Jolla Pharmaceutical Company
LJPC
$10.1M 0.09%
412,008
– –
LRMR icon
55
Larimar Therapeutics
LRMR
$434M
$9.96M 0.09%
23,973
+16,078
+204% +$6.73M
OSIR
56
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$9.71M 0.09%
499,193
– –
VIRX
57
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$9.63M 0.08%
15,238
– –
RXDX
58
DELISTED
Ignyta, Inc.
RXDX
$8.62M 0.08%
571,000
– –
NGNE icon
59
Neurogene
NGNE
$773M
$8.31M 0.07%
59,868
+485
+0.8% +$73.8K
SAGE
60
DELISTED
Sage Therapeutics
SAGE
$7.67M 0.07%
105,000
+30,000
+40% +$1.93M
LGND icon
61
Ligand Pharmaceuticals
LGND
$5.71B
$7.41M 0.07%
117,638
– –
CNCE
62
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.38M 0.06%
495,908
– –
ARWR icon
63
Arrowhead Research
ARWR
$12.3B
$7.22M 0.06%
1,009,509
-280,678
-22% -$1.93M
KPTI icon
64
Karyopharm Therapeutics
KPTI
$44.5M
$5.9M 0.05%
14,466
– –
EPZM
65
DELISTED
Epizyme, Inc
EPZM
$5.58M 0.05%
232,481
– –
AMRN
66
Amarin Corp
AMRN
$298M
$5.43M 0.05%
110,286
– –
AFMD
67
DELISTED
Affimed
AFMD
$5.39M 0.05%
40,000
– –
CMRX
68
DELISTED
Chimerix, Inc.
CMRX
$5.32M 0.05%
115,216
– –
AERI
69
DELISTED
Aerie Pharmaceuticals
AERI
$5.28M 0.05%
299,356
– –
VNDA icon
70
Vanda Pharmaceuticals
VNDA
$319M
$5.2M 0.05%
409,881
-1,340,349
-77% -$14.5M
MCRB icon
71
Seres Therapeutics
MCRB
$45.8M
$5.19M 0.05%
+6,250
New +$5.45M
CYTR
72
DELISTED
CytRx Corp
CYTR
$4.91M 0.04%
219,998
– –
ASMB icon
73
Assembly Biosciences
ASMB
$700M
$4.82M 0.04%
20,833
– –
RCPT
74
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$4.54M 0.04%
23,900
– –
JUNO
75
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.27M 0.04%
80,000
-20,000
-20% -$1.06M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2015 Portfolio in Review

As of Q2 2015, Julian Baker held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Julian Baker withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 46% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Julian Baker's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Julian Baker added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Julian Baker's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Julian Baker fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Julian Baker's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Julian Baker opened 10 new positions and closed 12 in Q2 2015.
  • Julian Baker's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.